Nasdaq Biotechnology (IBB) is a publicly traded the market company. As of May 20, 2026, IBB trades at $167.11 with a market cap of $0 and a P/E ratio of 0.00. IBB moved +2.20% today. Year to date, IBB is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $0.00 to $0.00. Rallies surfaces IBB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
IBB flat as biotech earnings setup and M&A optimism offset rate sensitivity: IBB was roughly flat on May 7, 2026 as gains in some large-cap biotech components were offset by broader risk-factor crosscurrents. The key near-term focus is mega-cap biotech earnings and deal chatter, with Gilead set to report after the close and recent pipeline M&A keeping the group supported.
| Metric | Value |
|---|---|
| Price | $167.11 |
| Market Cap | $0 |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $0.00 |
| 52-Week Low | $0.00 |
| Volume | 1.77M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
IBB analyst coverage data. Average price target: $0.00.